Urinary Uremic Toxin Signatures and the Metabolic Index of Gut Dysfunction (MIGD) in Autism Spectrum Disorder: A Stool-Phenotype-Stratified Analysis.
Urine toxin levels look the same across kids, but a new gut score moves with stool type, pointing to possible gut sub-groups in autism.
01Research in Context
What this study did
The team looked at urine from kids with autism and neurotypical peers.
They checked uremic toxins and a new gut score called MIGD.
Kids were grouped by stool type: normal, loose, or hard.
What they found
No single toxin was higher or lower in the autism group.
MIGD scores did shift across stool types, hinting at gut sub-types.
Results are early; more work is needed before clinical use.
How this fits with other research
Lussu et al. (2017) first saw urinary metabolite patterns in Italian kids with autism.
The new study widens that lens by adding stool-type splits, building on the 2017 base.
Dalton et al. (2014) found normal gut permeability in autism, which seems to clash.
The gap makes sense: permeability and toxin handling measure different gut jobs.
Root et al. (2017) also struck out with one urine marker (IAG), matching the null toxin finding here.
Why it matters
You now have a fresh reminder that gut signs in autism are messy.
Single urine tests are unlikely to give yes-or-no answers.
If a child presents with GI issues, track stool patterns and behavior, not exotic labs.
Share these data with parents to curb costly fringe testing.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Start a simple stool log for each client: note daily form, foods, and problem behaviors to spot patterns.
02At a glance
03Original abstract
Gut-derived uremic toxins may play a key role in neurodevelopmental conditions such as autism spectrum disorder (ASD) via host-microbe metabolic interactions. We evaluated five uremic toxins—p-cresyl sulfate (PCS), indoxyl sulfate (IS), trimethylamine N-oxide (TMAO), asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA)—in urine samples of 97 children with ASD and 71 neurotypical controls, stratified by Bristol Stool Chart (BSC) consistency types. Four of these toxins (PCS, IS, TMAO, ADMA) were integrated into a novel composite biomarker called the Metabolic Index of Gut Dysfunction (MIGD), while SDMA was measured as a complementary renal function marker. While individual metabolite levels showed no statistically significant differences, group-wise analysis by stool phenotype revealed distinct trends. ASD children with hard stools (BSC 1–2) showed elevated PCS levels and the MIGD score (median 555.3), reflecting phenolic fermentation dominance with reduced indolic detoxification. In contrast, children with loose stools (BSC 6–7) had the lowest MIGD values (median 109.8), driven by higher IS and lower ADMA concentrations, suggestive of enhanced indole metabolism. These findings indicate that MIGD may serve as a novel biomarker to stratify metabolic phenotypes in ASD, linking urinary metabolite patterns to gut function. Further validation in larger and longitudinal cohorts is warranted to confirm its potential utility in precision microbiota-targeted interventions.
International Journal of Molecular Sciences, 2025 · doi:10.3390/ijms262110475